According to MoneyDJ, pharmaceutical company Mediwound (1795) held an earnings call today (November 13) announcing it has extended its convertible bond (ECB) issuance deadline to February 3, 2027, to align with the launch timeline of two major U.S. drug candidates awaiting FDA final approval. The company also secured a credit facility of up to $100 million from Innobic, a PTT subsidiary, to refinance existing loans and improve financial flexibility. Management expects the two products, with a combined addressable market of approximately $3 billion, to significantly improve revenue, profitability, and cash flow once launched. One candidate, Cabozantinib (LP757), has an FDA review target date of December 23, 2026.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.